Abstract
Background:
Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response.
Methods:
We developed an “immunotumoroid” cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy. Immunotumoroids were developed from surgically resected renal cell carcinomas and bladder carcinomas selected for high tumor-infiltrating lymphocytes (TILs) and survived more than a month without media exchange. Immunohistochemistry was used to detect immune and non-immune cells in cryopreserved source tumors and the resulting immunotumoroids. Immunotumoroid response to ICIs (nivolumab, pembrolizumab, and durvalumab) and chemotherapy (cisplatin, gemcitabine, and paclitaxel) was monitored in real-time with Cytotox Red staining in an Incucyte device, and the immunotumoroid response was compared to retrospective clinical drug responses.
Results:
Six of the 13 cases tested grew viable immunotumoroid models, with failed cases attributed to extensive tumor tissue necrosis or excess lymphocytes preventing spheroid formation. One successfully cultured case was excluded from the study due to low TIL infiltration (<5%) in the primary tumor sample. The five remaining models contained immune cells (CD4+ and CD8+ T cells, and macrophages), non-immune cells (fibroblasts), and tumor cells. Chemotherapy and ICI drugs were tested in immunotumoroids from 5 cases and compared to clinical outcomes where data was available. Four/five models showed cell killing in response to chemotherapy and two/five showed sensitivity to ICI. In three cases, the immunotumoroid model accurately predicted the patient’s clinical response or non-response to ICIs or chemotherapy.
Conclusion:
Our immunotumoroid model replicated the multicellular nature of the tumor microenvironment sufficiently for preclinical ICI screening. This model could enable valuable insights into the complex interactions between cancer cells, the immune system, and the microenvironment. This is a feasibility study on a small number of cases, and additional studies with larger case numbers are required including correlation with clinical response.
Introduction
Patients with bladder and renal cancers may be treated with surgical resection, chemotherapy radiation therapy, or a combination of these treatments. However, in recent years, immune checkpoint inhibitor (ICI) therapy has emerged as a promising new treatment option including in the neoadjuvant setting for bladder cancer. Immune checkpoint proteins are localized to the surface of immune cells and act as “brakes” to prevent autoimmune responses. Tumor cells often produce ligands to these checkpoints as a mechanism of immune evasion; by blocking the immune checkpoints and preventing tumor cells from interacting with them, immunotherapy can help restore the immune system’s ability to recognize and attack cancer cells. Preclinical evaluation of the tumoral response to ICI therapy can provide valuable insights into the complex interactions between cancer cells, the immune system, and the tumor microenvironment (TME).
Microcancer models () are 3D tumor spheroid cultures that can be used to evaluate how a tumor responds to various treatments. Spheroids recapitulate in vivo tumor structure including the presence of an inner hypoxic region that is characteristic of solid tumors, allowing for a physiologically relevant representation of the tumor microenvironment compared to traditional 2D cell culture systems (, ). The spheroids can be placed in 96 well plates and immune checkpoint inhibitors can be added to the wells, and their effects on tumor growth, immune cell cytotoxicity, and the overall response of the cancer cells can be measured. Conventionally, microcancers used for drug screening are prepared from a tumor cell line instead of the patient’s specific tumor cells (). These tumor spheroids are usually monocellular, with effector immune cells added after aggregation to allow evaluation of the immune response (–).
Here we present an immunotumoroid model designed for the evaluation of ICI therapies on primary tumor cells acquired by biopsy or surgical resection. After tissue dissociation, tumor cells, stromal cells, and tumor-infiltrating lymphocytes (TILs) reassemble into a spheroid microcancer in a hanging drop culture. This model is scaffold‐free in that cells produce their own extracellular matrix (ECM) and there is no exogenous artificial ECM that could affect the drug response (). Our immunotumoroid model reflects the in vivo tumor heterogeneity of tumor cells, immune cells, and ECM and allows scalability of testing with standardization of measurements.
Methods
Tumor collection and cryopreservation
Surgically resected tumor samples (kidney and bladder cancer) were retrieved from the Mayo Clinic operating rooms by dedicated laboratory assistants immediately upon removal from the patient. The sample was rapidly processed for clinical care and tumor in excess of diagnosis was collected for this study. Tumor samples were cryopreserved by dicing into 1 mm cubes placing them in 1.5mL cryovials and suspending them in 1.0 mL CryoStor media (07955; Stemcell) per tube. The vials were placed in freezing containers (5100-0001; Thermo Fisher Scientific), and cooled the cells at a rate of -1°C/min until reaching -80°C. After overnight incubation at -80°C, the cryopreserved tumors were stored in liquid nitrogen for later use.
Immunotumoroid development
The cryopreserved tumors were mechanically and enzymatically dissociated using the Miltenyi Biotec tumor dissociation kit (#130-095-929) and the GentleMACS ™ Dissociator (#130-093-235) based on the manufacturer’s protocol. To generate the multicellular microcancer (immunotumoroid), 1.5 x 10 4 cells/well were loaded on a 96-well GravityPLUS Hanging Drop plate (InSphero, Schlieren, Switzerland) and incubated at 37°C. Cells were seeded at 1.5 x 10 4 cells/well to increase the inclusion of non-tumor cells, such as stromal cells and tumor-infiltrating lymphocytes. After 4 days of incubation (day -4), the aggregated microcancers were dropped into a 96-Well clear round bottom ultra-low attachment (ULA) plate (#7007 Corning) and cultured in DMEM/F12 media supplemented with 10% heat-inactivated human AB sera, primocin, glutamax, hepes, N-Acetyl-L-cysteine, Nicotinamide, B-27 Supplement, A83-01, insulin, EGF, and the therapeutic agents. The total volume of media per well was 240 μL. Cultures were incubated in a humidified atmosphere of 5% CO2 at 37°C.
Real-time monitoring of drug response in the immunotumoroid model
Initial cell viability was measured on day 0, after dropping the immunotumoroid but before drug dosing, and then evaluated at later time points by Incucyte Cytotox Red staining (#4632 Sartorius). Incucyte Cytotox Red is a highly sensitive nucleic acid dye for real-time quantification of cell death. As cell health begins to decline, the integrity of the plasma membrane is compromised, allowing the dye to enter the cell. Fluorescence increases 100-1000-fold upon binding to DNA. For each drug, we applied 5 log concentrations and just the Cmax concentration indicated in the main figures of the paper. The response to the other drug concentrations can be found in the Supplementary Figures. The Cmax of the drugs was obtained from relevant publications () and also the Micromedex website (https://www.micromedexsolutions.com/). The microcancer response to treatment was recorded by the Incucyte S3 Live-Cell Analysis Instrument (Sartorius, Germany) using the Incucyte Spheroid Analysis Software Module (# 9600-0019).
Cisplatin (Fresenius Kabi USA, LLC), gemcitabine (Athenex Pharmaceutical Division, LLC), and paclitaxel (Athenex Pharmaceutical Division, LLC) were used as chemotherapy drugs. For ICI drugs, pembrolizumab (Merck Sharp & Dohme LLC), nivolumab (E.R. Squibb & Sons, LLC), and durvalumab (AstraZeneca Pharmaceuticals LP) were used.
Immunohistochemistry
Immunohistochemical staining of 5 μm thick paraffin-embedded tissue sections was performed on an automated BenchMark ULTRA IHC/ISH Staining Module (Ventana Medical Systems, AZ) as follows. CD3 clone LN10 at 1/250 dilution, pretreatment with CC1 (Catalog # 950-224) 32 min at 100C, antibody for 32min at 36C, Optiview DAB detection (Catalog # 760-700). CD4 clone SP35, predilute, pretreatment with CC1 36 min at 95C, antibody for 32min at 36C, Ultraview DAB detection (Catalog # of 760-500). CD8 clone C8/144B at 1/250 dilution, pretreatment with CC1 32 min at 100C, antibody for 16 min at 36C, Optiview DAB detection. CD68 clone PG-M1 at 1/75 dilution with CC1 36 min at 95C, antibody for 32 min at 36C, Ultraview DAB detection. Vimentin clone V9, prediluted, pretreatment with CC1 32 min at 100C, antibody for 16 min at 36C, Optiview DAB detection. PD-L1 clone 22C3 at 1/50 dilution, pretreatment with CC1 64 min at 100C, antibody for 24min at 36C, Optiview +Amp DAB detection (Catalog # 760-099). PD-1 clone NAT105 at 1/300 dilution, pretreatment with CC1 32 min at 100C, antibody for 32 min at 36C, Optiview +Amp DAB detection.
Statistical analysis
Statistical analyses were performed using GraphPad Prism. The unpaired t test was used to determine the statistical significance between the two groups.
Results
The immunotumoroid model is optimized for the extended culture time required to monitor ICI response
This study evaluated the anti-tumor immune response of TILs, recognizing that the immunotumoroid model lacks a complete immune system and that the TILs’ anti-tumor cytotoxicity may be delayed in comparison to T cells in vivo. Additionally, most of the T cells in the TME have an exhausted and dysfunctional phenotype, and only a fraction are reactivated by the ICI treatment (). Due to the comparatively low immune cell diversity and lack of systemic factors in an immunotumoroid model versus the in vivo TME, reactivation of exhausted cytotoxic T cells and the manifestation of detectable cytotoxicity likely requires some time. We therefore designed our immunotumoroid model to survive extended periods by optimizing the volume and components of the culture medium to support long-term survival (see Methods). Figure 1 depicts a bladder immunotumoroid at multiple time points from day 0 until day 35. The tumor cell suspension is seeded on GravityPlus hanging drop plates on day -4 and the immunotumoroids are dropped into ULA plates on day 0. Even after 5 weeks of incubation without changing the media, the immunotumoroids are healthy with no sign of necrosis and apoptosis compared to the initial time points. By exchanging culture media, the immunotumoroids survived for over 65 days. This long-time survival was exhibited by all 5 cases that successfully formed immunotumoroids in this study, supporting the model’s suitability for ICI response evaluation.
Figure 1
The immunotumoroid formation
Among 13 collected surgically resected tumor samples, 6 of them had extensive necrosis that prevented the formation of the tumor spheroid (immunotumoroid) in the hanging drop system. Immune checkpoint inhibitors (ICIs) are the blocking antibodies and do not have any cytotoxic effect on tumor cells by themselves; by blocking checkpoint proteins from binding with their ligands ICIs prevent the “off” signal from being sent, allowing the tumor-specific T cells to kill the tumor cells (). Therefore, the prerequisite of any model to evaluate ICI response is the inclusion of tumor-specific T cells known as tumor infiltrated lymphocytes (TILs) (–). However, in our hands, an excess of TILs can prevent the formation of tumor spheroid. One of the collected tumor samples had ~ 40% TILs in the dissociated tumor cell suspension which was sufficient to prevent the formation of immunotumoroid.
The IHC staining of another tumor sample that successfully made tumor spheroid revealed less than 5% TILs in the primary tumor sample which made it ineligible as an immunotumoroid and was excluded from the study.
The immunotumoroid model retains characteristics of the primary tumor
A model for ICI response evaluation must include immune and non-immune cells of TME that play crucial roles in the response to immunotherapy. Case 1 is a renal tumor with a high T cell (CD3+) infiltration. Cytotoxic CD8+ and helper/regulatory CD4+ T cells were detected by IHC, and the tumor shows high PD-1 and PD-L1 expression (Figure 2). A portion of the tumor was processed and cultured as immunotumoroids before IHC staining which shows that the resulting immunotumoroids retained the different subsets of T cells required for anti-tumor and ICI response evaluation, as well as PD-1 and PD-L1 expression (Figure 3).
Figure 2
Figure 3
The complex interactions between cellular and chemical components of the TME support tumor growth, development, and metastasis; fibroblasts (vimentin) and macrophages (CD68) are essential contributors to tumor development and also contribute to immunotherapy resistance (–). Tumor-associated macrophages (TAMs) are the most heterogenous immune cells in the TME, are critical for tumor growth (, ), and play a major role in ICI resistance (–). Secretion of epidermal growth factor (EGF), platelet-derived growth factor (PDGF), IL-6, IL-8, and IL-10 and activation of the Wnt/β-catenin signaling pathway by TAMs can directly induce tumor cell proliferation (, ), while secretion of metalloproteinases (MMPs), growth factors, and angiopoietin-1 promotes angiogenesis to provide nutrient and oxygen support (, ). Additionally, TAMs can decrease ICI efficacy by 1) directly blocking CD8+ T cells’ anti-tumor functions and tumor infiltration ability (, , ), 2) expressing alternate immune checkpoints (i.e., VISTA) or 3) sequestering ICI antibodies (, , –). The IHC staining confirms that the immunotumoroid model retained the TAMs from the primary tumor as presented in Figure 3 by CD68 staining.
Cancer-associated fibroblasts (CAFs) are an essential component of the tumor stroma, with a major role in the physical support of tumor cells and enhancement of tumorigenesis (–). CAFs secrete various matrix proteins that play an essential role in the remodeling of tumor ECM (, ). Transforming growth factor-β (TGF-β) secreted by CAFs limits T cell infiltration into the tumor () while also downregulating the expression of MHC-II, CD80, and CD40 on the surface of dendritic cells in the TME, suppressing anti-tumor immunity (). Additionally, CAFs promote differentiation and recruitment of Tregs, which () inhibit CD8+ T cells function and promote T cell exhaustion (, ). The Case 1 immunotumoroid model shows the presence of CAFs and TAMs as detected by IHC. Taken together, this data shows that the immunotumoroid model retains the cellularity and the immune checkpoint expression profile of the original tumor (Figures 2, 3).
The immunotumoroid model accurately predicts the clinical response to chemotherapy
To test the model’s functionality and sensitivity to therapeutic agents, the immunotumoroids were treated with chemotherapy drugs cisplatin, gemcitabine, and paclitaxel. Cell killing was quantified by Cytotox Red staining; preexisting dead cells are normalized to untreated controls, and autofluorescence is normalized through untreated-unstained controls.
The response of renal (Case 1) and bladder (Case 2) immunotumoroids to chemotherapy agents at different time points are shown in Figure 4. Case 1 shows sensitivity to gemcitabine, cisplatin, and paclitaxel (Figures 4A–C) compared to the non-treated controls; interestingly, the sensitivity to cisplatin becomes apparent at a later time point and was not detectable on day 6. These experiments were performed on 5 log concentrations and only the Cmax concentrations are presented here (see Supplementary Figures for additional drug concentrations). Case 2 was also sensitive to gemcitabine and paclitaxel, but resistant to cisplatin (Figures 4D–F).
Figure 4
The immunotumoroid drug screen results were compared to the patient clinical response to the drug when available. The patient in Case 3 responded to paclitaxel and later responded to gemcitabine. The drug screen results for Case 3 align with this clinical response; Figure 5 shows that the immunotumoroid model responded well to both paclitaxel and gemcitabine beginning at day 7. Therefore, the immunotumoroid response to chemotherapeutic agents reflects the patient’s clinical response to these drugs. The patients of Cases 1, 4, and 5 did not receive any chemotherapy drug in their course of treatment. The patient from Case 2 had 1 cycle of gemcitabine and cisplatin but was not able to tolerate this due to renal impairment.
Figure 5
Immunotumoroid response to ICIs
After confirming the immunotumoroid model’s suitability for chemotherapeutic drug screening, we evaluated the model’s response to ICI therapy using PD-1 and PD-L1 inhibitors pembrolizumab, nivolumab, and durvalumab. Pembrolizumab and nivolumab both target PD-1, but we tested both drugs to account for the possibility of different outcomes due to structural differences between the antibodies (). Nivolumab and durvalumab were used in combination to evaluate possible synergistic effects observed in some cases from targeting both PD-1 and PD-L1 ().
Pembrolizumab and nivolumab/durvalumab combination therapy induced cytotoxicity in Case 1 (renal) immunotumoroids (Figures 6A, B). The response was apparent only at later time points (day 13 and day 20), which validates the need for long-term incubation of immunotumoroids in the context of ICI screening. Case 4 (bladder) immunotumoroids were resistant to both treatments compared to the untreated control (Figures 6C, D) Interestingly, Case 4 immunotumoroid viability increased after ICI treatment, which could be due to the hyperprogression phenomenon (–).
Figure 6
Immunotumoroid response to Immune Checkpoint Inhibitors aligns with clinical data
The patients in Case 3 and Case 5 have been treated with ICIs with different outcomes. Compared to the negative control, Case 5 immunotumoroids show sensitivity to both pembrolizumab and the combination of nivolumab and durvalumab (Figures 7A, B). This patient was diagnosed with clear cell renal cell carcinoma and underwent a year of pembrolizumab treatment after radical nephrectomy, and currently shows no evidence of disease. This clinical data correlates with the results of Case 5 immunotumoroid treatment with ICI.
Figure 7
Neither Pembrolizumab nor nivolumab/durvalumab therapies induced cell killing in Case 3 immunotumoroids (Figures 7C, D). Interestingly, immunotumoroid viability improved after ICI treatment compared to the untreated controls. The Case 3 patient had been diagnosed with renal carcinoma and progressed after receiving 5 doses of nivolumab. Therefore, the clinical response of Case 3 correlates with the immunotumoroid response to ICIs.
Clinical data and treatment outcomes of the cases are presented as a table in the Supplementary Data.
Discussion
Predicting a patient’s response to treatment can help ensure that patients most likely to benefit from the drug will receive the drug while those unlikely to respond will not have delays in receiving effective treatment and can avoid the cost and potential side effects of ineffective therapy. Using an immunotumoroid model, the tumor’s response to immunotherapy drugs can be assessed in a controlled environment, providing valuable information about the potential effectiveness of a particular treatment for a specific patient. A course of immunotherapy drugs is time-consuming and expensive; immunotumoroid models offer an efficient and cost-effective way to evaluate the response to these treatments. The data obtained by testing different immunotherapies on the immunotumoroid model can aid the selection of the most promising options and more importantly, avoid the administration of drugs in patients that do not respond. Figure 8 is a schematic representation of the immunotumoroid model.
Figure 8
While immunotumoroid models provide valuable insights into tumor biology and drug response, they cannot fully recapitulate the complexity and dynamic nature of the immune response in the human body. The immune system consists of a diverse population of immune cells with different functions and specificities; in a microcancer model, this diversity may be limited or absent. The absence of dendritic cells, natural killer cells, and/or myeloid cells, which interact with T cells and contribute to an effective immune response, can hinder the overall T cell reactivity observed in vitro. The body’s anti-cancer immune response is localized to the tumor site and is influenced by cytokines, chemokines, hormones, and regulatory feedback loops that can modulate immune cell activation, trafficking, and function. In a microcancer model, these systemic factors may be absent or not fully replicated, resulting in an incomplete representation of the complex immune regulation that occurs in vivo. Therefore, the efficiency of T cell reactions in microcancer models may be reduced compared to the in vivo setting. In consideration of these limitations when interpreting drug screen data and extrapolating findings to predict patient response, our immunotumoroid model was optimized for an extended time in culture.
There are inherent limitations, biases, and challenges in patient-derived microcancer models for cancer therapy, including size variability, lack of vascularization, tumor heterogeneity, biased selection of cells, biases in drug penetration, lack the complexity of the host immune responses, standardization of methods and protocols, and interpretation of results. 3D microcancers can vary significantly in size and morphology, which can affect their response to treatment and make it challenging to standardize experimental conditions. Microcancers lack a functional vascular system, which limits their ability to mimic the metabolic and drug diffusion properties of in vivo tumors. While microcancers can capture some aspects of tumor heterogeneity, they may not fully represent the genomic and phenotypic diversity found in primary tumors. The process of isolating and culturing cells to create microcancers can introduce biases, as only a subset of cells may survive and proliferate in the culture conditions. The way drugs penetrate and interact with the tumor can differ in microcancers compared to in vivo tumors. Microcancers may not fully capture the response of the immune system to immunotherapy, as they lack the complexity of in vivo immune responses and the potential effects of the host immune system on tumor growth. There is currently a lack of standardization in the methods and protocols used to generate and culture microcancers, which can lead to variability and inconsistent results. It can be challenging to interpret the results of organoid experiments, as the responses observed in vitro may not always translate to in vivo settings due to the limitations mentioned above.
Traditional chemotherapeutic agents are ideal for microcancer model performance evaluation. Chemotherapy remains the standard treatment approach for many cancers, and evaluating the efficacy of a microcancer model in predicting response to these drugs can be valuable. The diverse range of available chemotherapeutic agents represents different classes of drugs with different mechanisms of action, each validated in different cancer types; this diversity improves model performance assessment by enabling careful selection of drugs clinically approved for the model’s specific tumor type. In some cases, the availability of clinical data allows us to validate the predictions made by the microcancer model through correlation with clinical responses. Although our study is small, our data suggests that an immunotumoroid model has the potential to predict the patient’s response. The microcancer model must have T cells present. T cells play a central role in the anti-cancer immune response, as they are responsible for recognizing tumor antigens and eliminating tumor cells. ICI therapy targets T cells for reactivation, enhancing anti-tumor immune responses. Our immunotumoroid model incorporates T cells from the original tumor to increase the chance of including tumor-specific T cells, which are present in TILs at around 200 times the frequency of that found in PBMCs (–); this makes our model more physiologically relevant for evaluating the anti-tumor T cell response upon ICI treatment. The tumor-specific T cells in each immunotumoroid may or may not be responsive to the ICI treatment based on the immunosuppressive mechanisms they previously encountered in their particular TME.
It is worth noting that one should not expect the same level of cell killing from ICIs as from chemotherapeutic agents in an ex vivo microcancer model due to differences in the drugs’ mechanisms of action. ICIs enhance the activity of the immune system by blocking certain checkpoints that regulate immune responses against cancer cells; in contrast, chemotherapeutic agents directly kill both cancer cells and non-cancer cells. The cytotoxic effects of ICIs typically manifest over a longer time compared to chemotherapeutic agents. While chemotherapeutic agents act rapidly and with direct cytotoxicity on different cell populations regardless of individual characteristics, ICIs work by stimulating the immune system’s response against cancer cells; this involves the activation and proliferation of immune cells, which may extend the time required for full effect. Additionally, cells within a tumor exhibit significant heterogeneity that can result in a mixed ICI response timeline due to various factors, including the level of checkpoint expression in each cell population. Our data illustrates this difference in response time as Case 1 (Figures 6A, B) and Case 5 (Figures 7A, B) immunotumoroids become responsive to ICIs only after 13 and 21 days of treatment, while immunotumoroids responded to chemotherapy drugs within 4 -7 days of treatment (Figures 4, 5). Interestingly, the cytotoxic effect of ICIs on Case 5 and Case 3 immunotumoroids aligned with each patient’s clinical response; this strongly supports the immunotumoroid model’s capability to predict patient response to ICI therapy.
In Case 3 (Figures 7C, D) and Case 4 (Figure 6D), the immunotumoroid viability increased after ICI treatment, possibly the result of hyperprogression. Hyperprogressive disease (HPD) refers to the accelerated tumor growth observed in some cancer patients after treatment with ICIs (–). The HPD incidence rate is highly variable, ranging from 4 to 29% among different cancer types, and it may occur through several mechanisms. ICI-driven activation and expansion of PD-1+ regulatory T cells could support tumor growth and cultivate an immunosuppressive TME (, ). HPD could also be caused by ICI-driven activation of PD-1+ M2-TAMs, the release of protumor cytokines by activated Th17, and/or subclonal populations of cancer cells carrying mutations that result in oncogenic pathway activation by PD-1/PD-L1 axis blockade (, ).
In conclusion, we present a microcancer model designed to predict an individual tumor’s responses to chemotherapy and ICI treatment. This study demonstrates feasibility on a small number of cases, and additional studies with large case numbers are required including correlation with clinical response. Our immunotumoroid model shows the potential for a useful tool for the preclinical evaluation of ICIs and patient response prediction and holds promise for the evaluation of novel single-agent and combination therapy candidates. The need for combination therapies to overcome monotherapy resistance often limits ICI utility for many tumor types. We are optimizing our model to become eligible for the evaluation of combinational therapy in cases that are resistant to monotherapy. Currently, our ongoing studies are recruiting larger populations for this study and evaluation of other ICIs (e.g., CTLA-4, LAG-3, TIM-3) and assessment of new therapeutic approaches using multiple ICIs in combination or with targeted therapies. To correlate immunotumoroid model predictions with clinical responses we plan to collaborate with oncologists, potentially in a clinical trial setting, to validate the predictive value of the immunotumoroid model for immunotherapeutic response. Correlating the response of the immunotumoroid to immunotherapy in the model with the patient’s response to the same drug will allow us to better understand the translatability of the immunotumoroid model.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by The Ethics Committee of Mayo Clinic. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
AP: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. JC: Funding acquisition, Methodology, Supervision, Writing – review & editing. AF: Writing – review & editing. BL: Writing – review & editing. GV: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Mayo Clinic Central of Individual Medicine, the Biomarker Discovery Program, the Fred C. and Katherine B. Andersen Foundation the Mayo Clinic Graduate School of Biomedical Sciences and the NIH National Institute of Allergy and Infectious Diseases T32AI132165.
Acknowledgments
We thank Dr. Panos Anastasiadis and Ryan Feathers for their help and guidance in 3D microcancer culture. We thank Dr. Alan Penheiter for his constructive comments on the manuscript.
Conflict of interest
GV is the owner of WholeGenome LLC.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1356144/full#supplementary-material
References
1
VasmatzisGLiuMCRegantiSFeathersRWSmadbeckJJohnsonSHet al. Integration of comprehensive genomic analysis and functional screening of affected molecular pathways to inform cancer therapy. Mayo Clin Proc. (2020) 95:306–18. doi: 10.1016/j.mayocp.2019.07.019
2
NunesASBarrosASCostaECMoreiraAFCorreiaIJ. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. (2019) 116:206–26. doi: 10.1002/bit.26845
3
LvDHuZLuLLuHXuX. Three-dimensional cell culture: A powerful tool in tumor research and drug discovery. Oncol Lett. (2017) 14:6999–7010. doi: 10.3892/ol
4
CourauTBonnereauJChicoteauJBottoisHRemarkRAssante MirandaLet al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer. (2019) 7:74. doi: 10.1186/s40425-019-0553-9
5
IaiaIGammaitoniLCattaneoGGiraudoLDoniniCFiorinoEet al. Recruitment, infiltration, and cytotoxicity of HLA-independent killer lymphocytes in three-dimensional melanoma models. Cancers (Basel). (2021) 13. doi: 10.3390/cancers13102302
6
SaraivaDPMatiasATBragaSJacintoACabralMG. Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies. Front Oncol. (2020) 10:1543. doi: 10.3389/fonc.2020.01543
7
ListonDRDavisM. Clinically relevant concentrations of anticancer drugs: A guide for nonclinical studies. Clin Cancer Res. (2017) 23:3489–98. doi: 10.1158/1078-0432.CCR-16-3083
8
BudimirNThomasGDDolinaJSSalek-ArdakaniS. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res. (2022) 10:146–53. doi: 10.1158/2326-6066.CIR-21-0515
9
WiederTEigentlerTBrennerERockenM. Immune checkpoint blockade therapy. J Allergy Clin Immunol. (2018) 142:1403–14. doi: 10.1016/j.jaci.2018.02.042
10
van RooijNvan BuurenMMPhilipsDVeldsAToebesMHeemskerkBet al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. (2013) 31:e439–42. doi: 10.1200/JCO.2012.47.7521
11
PinhoMPPatenteTAFlatowEASallustoFBarbutoJAM. Frequency determination of breast tumor-reactive CD4 and CD8 T cells in humans: unveiling the antitumor immune response. Oncoimmunology. (2019) 8:1607674. doi: 10.1080/2162402X.2019.1607674
12
HallMSTeerJKYuXBranthooverHSnedalSRodriguez-ValentinMet al. Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. (2023) 11. doi: 10.1136/jitc-2023-007288
13
YuanYJiangYCSunCKChenQM. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep. (2016) 35:2499–515. doi: 10.3892/or.2016.4660
14
MamanSWitzIP. A history of exploring cancer in context. Nat Rev Cancer. (2018) 18:359–76. doi: 10.1038/s41568-018-0006-7
15
ErrartePLarrinagaGLopezJI. The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions. J Adv Res. (2020) 21:103–8. doi: 10.1016/j.jare.2019.09.004
16
FengBWuJShenBJiangFFengJ. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. (2022) 22:166. doi: 10.1186/s12935-022-02599-7
17
Eskandari-MalayeriFRezaeiM. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Front Immunol. (2022) 13:996145. doi: 10.3389/fimmu.2022.996145
18
MurrayPJWynnTA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. (2011) 11:723–37. doi: 10.1038/nri3073
19
MantovaniAMarchesiFMalesciALaghiLAllavenaP. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. (2017) 14:399–416. doi: 10.1038/nrclinonc.2016.217
20
GorchsLFernandez MoroCBankheadPKernKPSadeakIMengQet al. Human pancreatic carcinoma-associated fibroblasts promote expression of co-inhibitory markers on CD4(+) and CD8(+) T-cells. Front Immunol. (2019) 10:847. doi: 10.3389/fimmu.2019.00847
21
TeramotoKIgarashiTKataokaYIshidaMHanaokaJSumimotoHet al. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Lung Cancer. (2019) 137:56–63. doi: 10.1016/j.lungcan.2019.09.013
22
DouDRenXHanMXuXGeXGuYet al. Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway. Front Immunol. (2020) 11:2026. doi: 10.3389/fimmu.2020.02026
23
LakinsMAGhoraniEMunirHMartinsCPShieldsJD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells. Nat Commun. (2018) 9:948. doi: 10.1038/s41467-018-03347-0
24
JenaBCDasCKBharadwajDMandalM. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Biochim Biophys Acta Rev Cancer. (2020) 1874:188416. doi: 10.1016/j.bbcan.2020.188416
25
ArlauckasSPGarrisCSKohlerRHKitaokaMCuccareseMFYangKSet al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. (2017) 9. doi: 10.1126/scitranslmed.aal3604
26
DeNardoDGRuffellB. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. (2019) 19:369–82. doi: 10.1038/s41577-019-0127-6
27
PeranzoniELemoineJVimeuxLFeuilletVBarrinSKantari-MimounCet al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. (2018) 115:E4041–E50. doi: 10.1073/pnas.1720948115
28
ChamseddineANAssiTMirOChouaibS. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Pharmacol Ther. (2022) 231:107986. doi: 10.1016/j.pharmthera.2021.107986
29
KumariNChoiSH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res. (2022) 41:68. doi: 10.1186/s13046-022-02272-x
30
DebebeAMedinaVChenCYMahajanIMJiaCFuDet al. Wnt/beta-catenin activation and macrophage induction during liver cancer development following steatosis. Oncogene. (2017) 36:6020–9. doi: 10.1038/onc.2017.207
31
RiabovVGudimaAWangNMickleyAOrekhovAKzhyshkowskaJ. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. (2014) 5:75. doi: 10.3389/fphys.2014.00075
32
RibattiDNicoBCrivellatoEVaccaA. Macrophages and tumor angiogenesis. Leukemia. (2007) 21:2085–9. doi: 10.1038/sj.leu.2404900
33
LuDNiZLiuXFengSDongXShiXet al. Beyond T cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J Immunol Res. (2019) 2019:1919082. doi: 10.1155/2019/1919082
34
BlandoJSharmaAHigaMGZhaoHVenceLYadavSSet al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. (2019) 116:1692–7. doi: 10.1073/pnas.1811067116
35
DahanRSegaEEngelhardtJSelbyMKormanAJRavetchJV. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. (2015) 28:285–95. doi: 10.1016/j.ccell.2015.08.004
36
RodallecASicardGGiacomettiSCarréMPourroyBBouquetBet al. Erratum: From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. Int J Nanomed. (2019) 14:335. doi: 10.2147/IJN.S179290
37
SatoTOtaTWatanabeMImadaKNomizuMItoA. Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. Gynecol Oncol. (2009) 114:337–42. doi: 10.1016/j.ygyno.2009.04.004
38
PeiLLiuYLiuLGaoSGaoXFengYet al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. (2023) 22:29. doi: 10.1186/s12943-023-01731-z
39
LiLWeiJRDongJLinQGTangHJiaYXet al. Laminin gamma2-mediating T cell exclusion attenuates response to anti-PD-1 therapy. Sci Adv. (2021) 7. doi: 10.1126/sciadv.abc8346
40
Bekeredjian-DingISchaferMHartmannEPriesRParcinaMSchneiderPet al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology. (2009) 128:439–50. doi: 10.1111/j.1365-2567.2009.03134.x
41
CostaAKiefferYScholer-DahirelAPelonFBourachotBCardonMet al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. (2018) 33:463–79.e10. doi: 10.1016/j.ccell.2018.01.011
42
SawantDVYanoHChikinaMZhangQLiaoMLiuCet al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. (2019) 20:724–35. doi: 10.1038/s41590-019-0346-9
43
TurnisMESawantDVSzymczak-WorkmanALAndrewsLPDelgoffeGMYanoHet al. Interleukin-35 limits anti-tumor immunity. Immunity. (2016) 44:316–29. doi: 10.1016/j.immuni.2016.01.013
44
MahoneyKMFreemanGJMcDermottDF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. (2015) 37:764–82. doi: 10.1016/j.clinthera.2015.02.018
45
JiangYChenMNieHYuanY. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. (2019) 15:1111–22. doi: 10.1080/21645515.2019.1571892
46
AdashekJJKatoSFerraraRLo RussoGKurzrockR. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. (2020) 25:94–8. doi: 10.1634/theoncologist.2019-0636
47
CamellitiSLe NociVBianchiFMoscheniCArnaboldiFGaglianoNet al. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know. J Exp Clin Cancer Res. (2020) 39:236. doi: 10.1186/s13046-020-01721-9
48
DenisMDuruisseauxMBrevetMDumontetC. How can immune checkpoint inhibitors cause hyperprogression in solid tumors? Front Immunol. (2020) 11:492. doi: 10.3389/fimmu.2020.00492
49
KamadaTTogashiYTayCHaDSasakiANakamuraYet al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. (2019) 116:9999–10008. doi: 10.1073/pnas.1822001116
50
TokiMISyrigosNSyrigosK. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer. (2021) 149:277–86. doi: 10.1002/ijc.33429
51
ZhaoZBianJZhangJZhangTLuX. Hyperprogressive disease in patients suffering from solid Malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. Front Oncol. (2022) 12:843707. doi: 10.3389/fonc.2022.843707
52
KatoSGoodmanAWalavalkarVBarkauskasDASharabiAKurzrockR. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. (2017) 23:4242–50. doi: 10.1158/1078-0432.CCR-16-3133
53
AadGAbbottBAbbottDCAbed AbudAAbelingKAbhayasingheDKet al. Measurement of Azimuthal Anisotropy of Muons from Charm and Bottom Hadrons in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector. Phys Rev Lett. (2020) 124:082301. doi: 10.1103/PhysRevLett.124.082301
Summary
Keywords
immune checkpoint inhibitor (ICI), immunotumoroid, prediction of response to immune checkpoint inhibitor (ICI) therapy, tumor-infiltrating lymphocytes (TILs), microcancer, patient derived tumor spheroid
Citation
Pezeshki A, Cheville JC, Florio AB, Leibovich BC and Vasmatzis G (2024) Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model. Front. Immunol. 15:1356144. doi: 10.3389/fimmu.2024.1356144
Received
15 December 2023
Accepted
18 March 2024
Published
28 March 2024
Volume
15 - 2024
Edited by
Arya Mariam Roy, University at Buffalo, United States
Reviewed by
Maria Grazia Totaro, IFOM - The FIRC Institute of Molecular Oncology, Italy
Rahul M. Visalakshan, Genentech Inc., United States
Updates
Copyright
© 2024 Pezeshki, Cheville, Florio, Leibovich and Vasmatzis.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: George Vasmatzis, Vasmatzis.George@mayo.edu; John C. Cheville, Cheville.John@mayo.edu; Abdulmohammad Pezeshki, pezeshki.abdulmohammad@mayo.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.